StockData

Adaptive Biotechnologies vs Agenus

ADPT and AGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADPT and AGEN compare

Adaptive Biotechnologies is the larger company, worth 16 times as much as Agenus ($4.5B against $283M).

Adaptive Biotechnologies grew revenue faster over the last twelve months (50.1% versus 30.5% for Agenus).

Adaptive Biotechnologies scores higher on the StockData Score (12 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADPTAGEN
Size and price
Market cap$4.5B$283M
Share price$28.49$6.29
Change, 1 year102%45.3%
Change, 5 years1.3%−90.3%
Beta (5Y)0.511.01
Employees62481
StockData Score
Total score12 (better)3
Valuation score01 (better)
Growth score4 (better)2
Performance score3 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/S14.8×2.1× (better)
P/B31.8×–
EV/EBITDA–7.0×
FCF yield−0.53% (better)−34.8%
Growth
Revenue growth (TTM)50.1% (better)30.5%
Revenue growth, 5Y average23.0% (better)5.3%
Profitability
Gross margin75.6%99.5% (better)
Operating margin−12.2%27.3% (better)
Net margin−20.7%–
FCF margin−7.8% (better)−74.2%
Return on equity−39.6%–
Financial health
Debt / equity0.00–
Net debt / EBITDA–0.28
Interest coverage−3.3×0.6× (better)
Current ratio4.79 (better)0.34
Altman Z-score3.37 (better)−16.54
Piotroski F-score5–
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.6%31.7%
Held by insiders22.7%6.6%
Insider net buying, 12 months−$118M–
Superinvestors holding1–
Short interest, % of float9.3%18.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.